Seronegative patients vaccinated with cytomegalovirus gB-MF59 vaccine have evidence of neutralising antibody responses against gB early post-transplantation

Background: Human cytomegalovirus (HCMV) causes a ubiquitous infection which can pose a significant threat for immunocompromised individuals, such as those undergoing solid organ transplant (SOT). Arguably, the most successful vaccine studied to date is the recombinant glycoprotein-B (gB) with MF59...

Full description

Bibliographic Details
Main Authors: Ilona Baraniak, Ariane C. Gomes, Isabella Sodi, Toby Langstone, Emily Rothwell, Claire Atkinson, Sylvie Pichon, Fabienne Piras-Douce, Paul D. Griffiths, Matthew B. Reeves
Format: Article
Language:English
Published: Elsevier 2019-12-01
Series:EBioMedicine
Online Access:http://www.sciencedirect.com/science/article/pii/S2352396419307467
id doaj-08a927984721435f8ea3079281257f12
record_format Article
spelling doaj-08a927984721435f8ea3079281257f122020-11-25T01:30:02ZengElsevierEBioMedicine2352-39642019-12-01504554Seronegative patients vaccinated with cytomegalovirus gB-MF59 vaccine have evidence of neutralising antibody responses against gB early post-transplantationIlona Baraniak0Ariane C. Gomes1Isabella Sodi2Toby Langstone3Emily Rothwell4Claire Atkinson5Sylvie Pichon6Fabienne Piras-Douce7Paul D. Griffiths8Matthew B. Reeves9Institute for Immunity and Transplantation, UCL, Royal Free Campus, London NW3 2PF, United KingdomInstitute for Immunity and Transplantation, UCL, Royal Free Campus, London NW3 2PF, United KingdomInstitute for Immunity and Transplantation, UCL, Royal Free Campus, London NW3 2PF, United KingdomInstitute for Immunity and Transplantation, UCL, Royal Free Campus, London NW3 2PF, United KingdomInstitute for Immunity and Transplantation, UCL, Royal Free Campus, London NW3 2PF, United KingdomInstitute for Immunity and Transplantation, UCL, Royal Free Campus, London NW3 2PF, United KingdomClinical Development, Sanofi Pasteur, Marcy l'Etoile, FranceResearch and Non-Clinical Safety, Sanofi Pasteur, Marcy l'Etoile, FranceInstitute for Immunity and Transplantation, UCL, Royal Free Campus, London NW3 2PF, United KingdomInstitute for Immunity and Transplantation, UCL, Royal Free Campus, London NW3 2PF, United Kingdom; Corresponding author.Background: Human cytomegalovirus (HCMV) causes a ubiquitous infection which can pose a significant threat for immunocompromised individuals, such as those undergoing solid organ transplant (SOT). Arguably, the most successful vaccine studied to date is the recombinant glycoprotein-B (gB) with MF59 adjuvant which, in 3 Phase II trials, demonstrated 43–50% efficacy in preventing HCMV acquisition in seronegative healthy women or adolescents and reduction in virological parameters after SOT. However, the mechanism of vaccine protection in seronegative recipients remains undefined. Methods: We evaluated samples from the cohort of seronegative SOT patients enroled in the Phase II glycoprotein-B/MF59 vaccine trial who received organs from seropositive donors. Samples after SOT (0–90 days) were tested by real-time quantitative PCR for HCMV DNA. Anti-gB antibody levels were measured by ELISA. Neutralization was measured as a decrease in infectivity for fibroblast cell cultures revealed by expression of immediate-early antigens. Findings: Serological analyses revealed a more rapid increase in the humoral response against gB post transplant in vaccine recipients than in those randomised to receive placebo. Importantly, a number of patient sera displayed HCMV neutralising responses – neutralisation which was abrogated by pre-absorbing the sera with recombinant gB. Interpretation: We hypothesise that the vaccine primed the immune system of seronegative recipients which, when further challenged with virus at time of transplant, allowed the host to mount rapid immunological humoral responses even under conditions of T cell immune suppression during transplantation. Keywords: Cytomegalovirus, Vaccination, Antibody responses, Prime-boosthttp://www.sciencedirect.com/science/article/pii/S2352396419307467
collection DOAJ
language English
format Article
sources DOAJ
author Ilona Baraniak
Ariane C. Gomes
Isabella Sodi
Toby Langstone
Emily Rothwell
Claire Atkinson
Sylvie Pichon
Fabienne Piras-Douce
Paul D. Griffiths
Matthew B. Reeves
spellingShingle Ilona Baraniak
Ariane C. Gomes
Isabella Sodi
Toby Langstone
Emily Rothwell
Claire Atkinson
Sylvie Pichon
Fabienne Piras-Douce
Paul D. Griffiths
Matthew B. Reeves
Seronegative patients vaccinated with cytomegalovirus gB-MF59 vaccine have evidence of neutralising antibody responses against gB early post-transplantation
EBioMedicine
author_facet Ilona Baraniak
Ariane C. Gomes
Isabella Sodi
Toby Langstone
Emily Rothwell
Claire Atkinson
Sylvie Pichon
Fabienne Piras-Douce
Paul D. Griffiths
Matthew B. Reeves
author_sort Ilona Baraniak
title Seronegative patients vaccinated with cytomegalovirus gB-MF59 vaccine have evidence of neutralising antibody responses against gB early post-transplantation
title_short Seronegative patients vaccinated with cytomegalovirus gB-MF59 vaccine have evidence of neutralising antibody responses against gB early post-transplantation
title_full Seronegative patients vaccinated with cytomegalovirus gB-MF59 vaccine have evidence of neutralising antibody responses against gB early post-transplantation
title_fullStr Seronegative patients vaccinated with cytomegalovirus gB-MF59 vaccine have evidence of neutralising antibody responses against gB early post-transplantation
title_full_unstemmed Seronegative patients vaccinated with cytomegalovirus gB-MF59 vaccine have evidence of neutralising antibody responses against gB early post-transplantation
title_sort seronegative patients vaccinated with cytomegalovirus gb-mf59 vaccine have evidence of neutralising antibody responses against gb early post-transplantation
publisher Elsevier
series EBioMedicine
issn 2352-3964
publishDate 2019-12-01
description Background: Human cytomegalovirus (HCMV) causes a ubiquitous infection which can pose a significant threat for immunocompromised individuals, such as those undergoing solid organ transplant (SOT). Arguably, the most successful vaccine studied to date is the recombinant glycoprotein-B (gB) with MF59 adjuvant which, in 3 Phase II trials, demonstrated 43–50% efficacy in preventing HCMV acquisition in seronegative healthy women or adolescents and reduction in virological parameters after SOT. However, the mechanism of vaccine protection in seronegative recipients remains undefined. Methods: We evaluated samples from the cohort of seronegative SOT patients enroled in the Phase II glycoprotein-B/MF59 vaccine trial who received organs from seropositive donors. Samples after SOT (0–90 days) were tested by real-time quantitative PCR for HCMV DNA. Anti-gB antibody levels were measured by ELISA. Neutralization was measured as a decrease in infectivity for fibroblast cell cultures revealed by expression of immediate-early antigens. Findings: Serological analyses revealed a more rapid increase in the humoral response against gB post transplant in vaccine recipients than in those randomised to receive placebo. Importantly, a number of patient sera displayed HCMV neutralising responses – neutralisation which was abrogated by pre-absorbing the sera with recombinant gB. Interpretation: We hypothesise that the vaccine primed the immune system of seronegative recipients which, when further challenged with virus at time of transplant, allowed the host to mount rapid immunological humoral responses even under conditions of T cell immune suppression during transplantation. Keywords: Cytomegalovirus, Vaccination, Antibody responses, Prime-boost
url http://www.sciencedirect.com/science/article/pii/S2352396419307467
work_keys_str_mv AT ilonabaraniak seronegativepatientsvaccinatedwithcytomegalovirusgbmf59vaccinehaveevidenceofneutralisingantibodyresponsesagainstgbearlyposttransplantation
AT arianecgomes seronegativepatientsvaccinatedwithcytomegalovirusgbmf59vaccinehaveevidenceofneutralisingantibodyresponsesagainstgbearlyposttransplantation
AT isabellasodi seronegativepatientsvaccinatedwithcytomegalovirusgbmf59vaccinehaveevidenceofneutralisingantibodyresponsesagainstgbearlyposttransplantation
AT tobylangstone seronegativepatientsvaccinatedwithcytomegalovirusgbmf59vaccinehaveevidenceofneutralisingantibodyresponsesagainstgbearlyposttransplantation
AT emilyrothwell seronegativepatientsvaccinatedwithcytomegalovirusgbmf59vaccinehaveevidenceofneutralisingantibodyresponsesagainstgbearlyposttransplantation
AT claireatkinson seronegativepatientsvaccinatedwithcytomegalovirusgbmf59vaccinehaveevidenceofneutralisingantibodyresponsesagainstgbearlyposttransplantation
AT sylviepichon seronegativepatientsvaccinatedwithcytomegalovirusgbmf59vaccinehaveevidenceofneutralisingantibodyresponsesagainstgbearlyposttransplantation
AT fabiennepirasdouce seronegativepatientsvaccinatedwithcytomegalovirusgbmf59vaccinehaveevidenceofneutralisingantibodyresponsesagainstgbearlyposttransplantation
AT pauldgriffiths seronegativepatientsvaccinatedwithcytomegalovirusgbmf59vaccinehaveevidenceofneutralisingantibodyresponsesagainstgbearlyposttransplantation
AT matthewbreeves seronegativepatientsvaccinatedwithcytomegalovirusgbmf59vaccinehaveevidenceofneutralisingantibodyresponsesagainstgbearlyposttransplantation
_version_ 1725094115631169536